Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023 16:02 ET
|
Arcutis Biotherapeutics, Inc.
Achieved total revenues of $5.2 million in the second quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $4.8 million, a 72% increase compared to the first quarter of...
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
July 17, 2023 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Coverage at CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States was effective July 5All three of the largest pharmacy benefit managers in the United States have now included...
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023 16:02 ET
|
Arcutis Biotherapeutics, Inc.
Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarterContinued expansion of commercial...
Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
April 28, 2023 16:01 ET
|
Arcutis Biotherapeutics, Inc.
First novel steroid-free topical with a new mechanism of action approved for plaque psoriasis in over 25 yearsFirst ZORYVE approval outside of the U.S. marks key milestone for Arcutis WESTLAKE...
Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
April 05, 2023 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Eight additional national and regional health plans are now covering ZORYVE for plaque psoriasisZORYVE is a once-daily, steroid-free cream approved for use in both adults and adolescents with plaque...
Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis
January 14, 2023 04:00 ET
|
Arcutis Biotherapeutics, Inc.
During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of clear or...
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
December 19, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Regulatory submission for the expanded indication is supported by data from two recently completed 4-week Maximal Usage Systemic Exposure (MUSE) studies in children ages 2 to 11 years with plaque...
Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology
November 28, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Newly published phase 2b trial data show those treated with roflumilast cream had significantly greater improvements in itch compared to those treated with vehicle by Week 2 as assessed by the Worst...
Global Psoriasis Therapeutics Market to Reach $55.8 Billion by 2031: Says AMR
October 23, 2022 03:30 ET
|
Allied Market Research
Portland, OR, Oct. 23, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Psoriasis Therapeutics Market was estimated at $22.9 billion in 2021 and is...
Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis
September 20, 2022 11:07 ET
|
Arcutis Biotherapeutics, Inc.
Roflumilast cream showed higher efficacy compared to vehicle in both Phase 3 studies on the primary efficacy endpoint of Investigator Global Assessment (IGA) success, with 40% of roflumilast cream...